Skip to main content
Top
Published in: Neurological Sciences 1/2013

01-05-2013 | PECULIAR CLINICAL ASPECTS OF MIGRAINE

Dopaminergic symptoms in migraine

Authors: Piero Barbanti, L. Fofi, C. Aurilia, G. Egeo

Published in: Neurological Sciences | Special Issue 1/2013

Login to get access

Abstract

Migraine pain is often preceded, accompanied and followed by dopaminergic symptoms (premonitory yawning and somnolence, accompanying nausea and vomiting, postdromal somnolence, euphoria and polyuria). After reviewing evidence from pharmacological, biochemical, genetic and animal experimental studies on the relationship between dopamine and migraine, and matching these data with patients’ clinical features, we postulate that migraine attacks could be characterized by an ictal dopamine release in a subject with dopamine receptor hypersensitivity due to a chronic dopaminergic deficit synergistic to serotoninergic impairment. Our review suggests that when the attack begins, a low dopamine plasma concentration stimulates hypersensitive central presynaptic dopamine receptors thus causing prodromal symptoms such as yawning and somnolence. Increasing dopamine levels, though still insufficient to stop trigeminovascular activation, stimulate postsynaptic dopamine receptors thus inducing nausea, vomiting and hypotension. Finally, dopamine levels slowly return to baseline, giving rise to somnolence and fatigue, but, in some cases, continue to rise triggering postdromal symptoms such as euphoria and polyuria.
Literature
2.
3.
go back to reference Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders. 2nd edn. Cephalalgia 24(1):1–160CrossRef Headache Classification Subcommittee of the International Headache Society (2004) The International Classification of Headache Disorders. 2nd edn. Cephalalgia 24(1):1–160CrossRef
4.
go back to reference Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G (1991) Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 14:91–95PubMedCrossRef Blin O, Azulay JP, Masson G, Aubrespy G, Serratrice G (1991) Apomorphine-induced yawning in migraine patients: enhanced responsiveness. Clin Neuropharmacol 14:91–95PubMedCrossRef
5.
go back to reference Del Bene E, Poggioni M, De Tommasi F (1994) Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 34:536–538PubMedCrossRef Del Bene E, Poggioni M, De Tommasi F (1994) Video assessment of yawning induced by sublingual apomorphine in migraine. Headache 34:536–538PubMedCrossRef
6.
go back to reference Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C et al (1997) Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 20:36–41PubMedCrossRef Cerbo R, Barbanti P, Buzzi MG, Fabbrini G, Brusa L, Roberti C et al (1997) Dopamine hypersensitivity in migraine: role of the apomorphine test. Clin Neuropharmacol 20:36–41PubMedCrossRef
7.
go back to reference Bussone G, Boiardi A, La Mantia L, Frediani F, Lamperti E, Peccarisi C et al (1986) Clinical usefulness of a dopaminergic agonist in headache diagnosis. Int J Clin Pharmacol Res 6:23–26PubMed Bussone G, Boiardi A, La Mantia L, Frediani F, Lamperti E, Peccarisi C et al (1986) Clinical usefulness of a dopaminergic agonist in headache diagnosis. Int J Clin Pharmacol Res 6:23–26PubMed
8.
go back to reference Fanciullacci M, Michelacci S, Curradi C, Sicuteri F (1980) Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 20:99–102PubMedCrossRef Fanciullacci M, Michelacci S, Curradi C, Sicuteri F (1980) Hyperresponsiveness of migraine patients to the hypotensive action of bromocriptine. Headache 20:99–102PubMedCrossRef
9.
go back to reference Nagel-Leiby S, Welch KM, D’Andrea G, Grunfeld S, Brown E (1990) Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia 10:317–329PubMedCrossRef Nagel-Leiby S, Welch KM, D’Andrea G, Grunfeld S, Brown E (1990) Event-related slow potentials and associated catecholamine function in migraine. Cephalalgia 10:317–329PubMedCrossRef
10.
go back to reference Castillo J, Martinez F, Suarez C, Naveiro J, Lema M, Noya M (1996) Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia 16:56–61PubMedCrossRef Castillo J, Martinez F, Suarez C, Naveiro J, Lema M, Noya M (1996) Cerebrospinal fluid tyrosine and 3,4-dihydroxyphenylacetic acid levels in migraine patients. Cephalalgia 16:56–61PubMedCrossRef
11.
go back to reference Gruber HJ, Bernecker C, Pailer S, Lechner A, Horejsi R, Möller R et al (2010) Increased dopamine is associated with the cGMP and homocysteine pathway in female migraineurs. Headache 50:109–116PubMedCrossRef Gruber HJ, Bernecker C, Pailer S, Lechner A, Horejsi R, Möller R et al (2010) Increased dopamine is associated with the cGMP and homocysteine pathway in female migraineurs. Headache 50:109–116PubMedCrossRef
12.
go back to reference D’Andrea G, Granella F, Perini F, Farruggio A, Leone M, Bussone G (2006) Platelet levels of dopamine are increased in migraine and cluster headache. Headache 46:585–591PubMedCrossRef D’Andrea G, Granella F, Perini F, Farruggio A, Leone M, Bussone G (2006) Platelet levels of dopamine are increased in migraine and cluster headache. Headache 46:585–591PubMedCrossRef
13.
go back to reference D’Andrea G, D’Arrigo A, Dalle Caerbonare M, Leon A (2012) Pathogenesis of migraine: role of neuromodulators. Headache 52:1155–1163PubMedCrossRef D’Andrea G, D’Arrigo A, Dalle Caerbonare M, Leon A (2012) Pathogenesis of migraine: role of neuromodulators. Headache 52:1155–1163PubMedCrossRef
14.
go back to reference Barbanti P, Bronzetti E, Ricci A, Cerbo R, Fabbrini G, Buzzi MG et al (1996) Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci Lett 29(207):73–76CrossRef Barbanti P, Bronzetti E, Ricci A, Cerbo R, Fabbrini G, Buzzi MG et al (1996) Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine? Neurosci Lett 29(207):73–76CrossRef
15.
go back to reference Barbanti P, Fabbrini G, Ricci A, Pascali MP, Bronzetti E, Amenta F et al (2000) Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia 20:15–19PubMedCrossRef Barbanti P, Fabbrini G, Ricci A, Pascali MP, Bronzetti E, Amenta F et al (2000) Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia 20:15–19PubMedCrossRef
16.
go back to reference Ghosh J, Pradhan S, Mittal B (2013) Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromolecular Med 15:61–73PubMedCrossRef Ghosh J, Pradhan S, Mittal B (2013) Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility. Neuromolecular Med 15:61–73PubMedCrossRef
17.
go back to reference Todt U, Netzer C, Toliat M, Heinze A, Goebel I, Nürnberg P et al (2009) New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 125:265–279PubMedCrossRef Todt U, Netzer C, Toliat M, Heinze A, Goebel I, Nürnberg P et al (2009) New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet 125:265–279PubMedCrossRef
18.
go back to reference Peroutka SJ, Price SC, Wilhoit TL, Jones KW (1998) Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med 4:14–21PubMed Peroutka SJ, Price SC, Wilhoit TL, Jones KW (1998) Comorbid migraine with aura, anxiety, and depression is associated with dopamine D2 receptor (DRD2) NcoI alleles. Mol Med 4:14–21PubMed
19.
go back to reference Asuni C, Cherchi A, Congiu D, Piccardi MP, Del Zompo M, Stochino ME (2007) Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8:185–189PubMedCrossRef Asuni C, Cherchi A, Congiu D, Piccardi MP, Del Zompo M, Stochino ME (2007) Association study between clinical response to rizatriptan and some candidate genes. J Headache Pain 8:185–189PubMedCrossRef
20.
go back to reference Stochino ME, Asuni C, Congiu D, Del Zompo M, Severino G (2003) Association study between the phenotype migraine without aura-panic disorder and dopaminergic receptor genes. Pharmacol Res 48:531–534PubMedCrossRef Stochino ME, Asuni C, Congiu D, Del Zompo M, Severino G (2003) Association study between the phenotype migraine without aura-panic disorder and dopaminergic receptor genes. Pharmacol Res 48:531–534PubMedCrossRef
21.
go back to reference Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51:781–786PubMedCrossRef Del Zompo M, Cherchi A, Palmas MA, Ponti M, Bocchetta A, Gessa GL, Piccardi MP (1998) Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology 51:781–786PubMedCrossRef
22.
go back to reference Rebaudengo N, Rainero I, Parziale A, Rosina F, Pavanelli E, Rubino E et al (2004) Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. Cephalalgia 24:503–507PubMedCrossRef Rebaudengo N, Rainero I, Parziale A, Rosina F, Pavanelli E, Rubino E et al (2004) Lack of interaction between a polymorphism in the dopamine D2 receptor gene and the clinical features of migraine. Cephalalgia 24:503–507PubMedCrossRef
23.
go back to reference Mochi M, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Scapoli C, Montagna P (2003) A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. Neurol Sci 23:301–305PubMedCrossRef Mochi M, Cevoli S, Cortelli P, Pierangeli G, Soriani S, Scapoli C, Montagna P (2003) A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. Neurol Sci 23:301–305PubMedCrossRef
24.
go back to reference Cevoli S, Mochi M, Scapoli C, Marzocchi N, Pierangeli G, Pini LA et al (2006) Genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol 13:1009–1013PubMedCrossRef Cevoli S, Mochi M, Scapoli C, Marzocchi N, Pierangeli G, Pini LA et al (2006) Genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol 13:1009–1013PubMedCrossRef
25.
26.
go back to reference Cao Y, Aurora SK, Nagesh V, Patel SC, Welch KM (2002) Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59:72–78PubMedCrossRef Cao Y, Aurora SK, Nagesh V, Patel SC, Welch KM (2002) Functional MRI-BOLD of brainstem structures during visually triggered migraine. Neurology 59:72–78PubMedCrossRef
27.
go back to reference Barbanti P, Fabbrini G, Vanacore N, Rum A, Lenzi GL, Meco G, Cerbo R (2000) Dopamine and migraine: does Parkinson’s disease modify migraine course? Cephalalgia 20:720–723PubMed Barbanti P, Fabbrini G, Vanacore N, Rum A, Lenzi GL, Meco G, Cerbo R (2000) Dopamine and migraine: does Parkinson’s disease modify migraine course? Cephalalgia 20:720–723PubMed
28.
go back to reference Cubo E, Kompoliti K, Leurgans SE, Raman R (2004) Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol 27:30–32PubMedCrossRef Cubo E, Kompoliti K, Leurgans SE, Raman R (2004) Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol 27:30–32PubMedCrossRef
29.
go back to reference Charbit AR, Akerman S, Goadsby PJ (2009) Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex. J Pharmacol Exp Ther 331:752–763PubMedCrossRef Charbit AR, Akerman S, Goadsby PJ (2009) Comparison of the effects of central and peripheral dopamine receptor activation on evoked firing in the trigeminocervical complex. J Pharmacol Exp Ther 331:752–763PubMedCrossRef
30.
go back to reference Charbit AR, Akerman S, Goadsby PJ (2011) Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. Pain 152:2365–2376PubMedCrossRef Charbit AR, Akerman S, Goadsby PJ (2011) Trigeminocervical complex responses after lesioning dopaminergic A11 nucleus are modified by dopamine and serotonin mechanisms. Pain 152:2365–2376PubMedCrossRef
31.
go back to reference Lai M, Loi V, Pisano MR, Del Zompo M (1997) Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain. Int J Clin Pharmacol Res 17:101–103PubMed Lai M, Loi V, Pisano MR, Del Zompo M (1997) Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain. Int J Clin Pharmacol Res 17:101–103PubMed
32.
go back to reference Somerville BW, Herrmann WM (1978) Migraine prophylaxis with Lisuride hydrogen maleate—a double blind study of Lisuride versus placebo. Headache 18:75–79PubMedCrossRef Somerville BW, Herrmann WM (1978) Migraine prophylaxis with Lisuride hydrogen maleate—a double blind study of Lisuride versus placebo. Headache 18:75–79PubMedCrossRef
33.
go back to reference Bussone G, Cerbo R, Martucci N, Micieli G, Zanferrari C, Grazzi L et al (1999) Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache 39:426–431PubMedCrossRef Bussone G, Cerbo R, Martucci N, Micieli G, Zanferrari C, Grazzi L et al (1999) Alpha-dihydroergocryptine in the prophylaxis of migraine: a multicenter double-blind study versus flunarizine. Headache 39:426–431PubMedCrossRef
34.
go back to reference Wöber C, Brücke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I (1994) Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 14:235–240PubMedCrossRef Wöber C, Brücke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I (1994) Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 14:235–240PubMedCrossRef
35.
go back to reference Cupini LM, Troisi E, Placidi F, Diomedi M, Silvestrini M, Argiro G, Bernardi G (1999) Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia 19:27–31PubMedCrossRef Cupini LM, Troisi E, Placidi F, Diomedi M, Silvestrini M, Argiro G, Bernardi G (1999) Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study. Cephalalgia 19:27–31PubMedCrossRef
36.
go back to reference Waelkens J (1984) Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 4:85–90PubMedCrossRef Waelkens J (1984) Dopamine blockade with domperidone: bridge between prophylactic and abortive treatment of migraine? A dose-finding study. Cephalalgia 4:85–90PubMedCrossRef
37.
go back to reference Marmura J (2012) Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 14:27–35PubMedCrossRef Marmura J (2012) Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 14:27–35PubMedCrossRef
Metadata
Title
Dopaminergic symptoms in migraine
Authors
Piero Barbanti
L. Fofi
C. Aurilia
G. Egeo
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Neurological Sciences / Issue Special Issue 1/2013
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-013-1415-8

Other articles of this Special Issue 1/2013

Neurological Sciences 1/2013 Go to the issue